Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

FHD-609

Small molecule · Degrader of bromodomain-containing protein 9 (BRD9) · developed by Foghorn Therapeutics

Phase 1 Most advanced trial (none active)
FHTX Developer
1 Registered trials

What is FHD-609?

FHD-609 is a protein degrader that binds BRD9, a component of one form of the BAF chromatin remodeling complex, and recruits an E3 ligase complex to direct BRD9 for degradation. It is studied in advanced synovial sarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
bromodomain-containing protein 9 (BRD9)
Mechanism
Degrader of bromodomain-containing protein 9 (BRD9)
Pathways
BAF complex function, ubiquitin-mediated proteasomal degradation
Therapy area
Oncology
Developer
Foghorn Therapeutics Inc. (FHTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04965753 Phase 1 Advanced Synovial Sarcoma Terminated FHTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Synovial Sarcoma

Other drugs acting on BRD9

Sendegobresib Phase 1

More from Foghorn Therapeutics

Camibirstat Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the FHTX page.

Follow FHTX, the company behind FHD-609

See FHTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FHTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.